Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$984M |
| 2 |
State Street Utilities Select Sector SPDR ETF
XLU
|
+$406M |
| 3 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$363M |
| 4 |
Comcast
CMCSA
|
+$305M |
| 5 |
DuPont de Nemours
DD
|
+$229M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.98B |
| 2 |
Linde
LIN
|
+$1.14B |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$976M |
| 4 |
AGN
Allergan plc
AGN
|
+$735M |
| 5 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$469M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 9.7% |
| 2 | Financials | 4.92% |
| 3 | Consumer Discretionary | 4.46% |
| 4 | Healthcare | 4.33% |
| 5 | Communication Services | 4.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2501
Arcus Biosciences
RCUS
$3.64B
| $1.29M | ﹤0.01% |
52,149
+37,235
| +250% | +$1M |
|
|
XENT
2502
PUT
DELISTED
Intersect ENT, Inc
XENT
| $1.29M | ﹤0.01% |
+95,200
| New | +$1.11M |
|
|
CPRX
2503
DELISTED
Catalyst Pharmaceutical
CPRX
| $1.29M | ﹤0.01% |
278,355
+23,672
| +9% | +$106K |
|
|
RODI
2504
DELISTED
iPath Return on Disability ETN
RODI
| $1.29M | ﹤0.01% |
16,500
| – | – |
|
|
CRC
2505
PUT
DELISTED
California Resources Corporation
CRC
| $1.28M | ﹤0.01% |
1,052,100
+2,300
| +0.2% | +$3.89K |
|
2506
Altimmune
ALT
$599M
| $1.28M | ﹤0.01% |
+119,715
| New | +$658K |
|
2507
MGP Ingredients
MGPI
$375M
| $1.27M | ﹤0.01% |
34,666
+8,169
| +31% | +$292K |
|
2508
UMB Financial
UMBF
$11.1B
| $1.27M | ﹤0.01% |
24,673
+8,993
| +57% | +$441K |
|
2509
OraSure Technologies
OSUR
$279M
| $1.27M | ﹤0.01% |
109,102
-9,320
| -8% | -$121K |
|
2510
PUT
Under Armour
UAA
$2.6B
| $1.27M | ﹤0.01% |
130,200
-32,400
| -20% | -$307K |
|
2511
Lantheus
LNTH
$6.59B
| $1.27M | ﹤0.01% |
88,704
+28,860
| +48% | +$381K |
|
2512
PUT
Warner Bros
WBD
$67.1B
| $1.27M | ﹤0.01% |
+60,000
| New | +$1.3M |
|
|
SGI
2513
PUT
Somnigroup International
SGI
$13.7B
| $1.27M | ﹤0.01% |
70,400
-5,200
| -7% | -$74.6K |
|
2514
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
$23.8B
| $1.26M | ﹤0.01% |
19,804
-77,140
| -80% | -$4.55M |
|
2515
CALL
Microchip Technology
MCHP
$46B
| $1.26M | ﹤0.01% |
24,000
-189,800
| -89% | -$8.54M |
|
2516
CALL
Aecom
ACM
$9.75B
| $1.26M | ﹤0.01% |
33,600
+4,900
| +17% | +$175K |
|
|
DOOR
2517
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $1.26M | ﹤0.01% |
16,230
+3,876
| +31% | +$235K |
|
2518
Aurinia Pharmaceuticals
AUPH
$2.11B
| $1.26M | ﹤0.01% |
77,686
| – | – |
|
2519
Invesco Mortgage Capital
IVR
$805M
| $1.26M | ﹤0.01% |
33,747
+18,576
| +122% | +$639K |
|
2520
CALL
Monster Beverage
MNST
$88.5B
| $1.26M | ﹤0.01% |
36,400
-18,600
| -34% | -$607K |
|
2521
Amphastar Pharmaceuticals
AMPH
$916M
| $1.26M | ﹤0.01% |
56,068
+12,793
| +30% | +$234K |
|
2522
PUT
United States Natural Gas Fund
UNG
$478M
| $1.25M | ﹤0.01% |
30,575
-59,950
| -66% | -$2.85M |
|
2523
PUT
Stanley Black & Decker
SWK
$15.7B
| $1.25M | ﹤0.01% |
9,000
-5,900
| -40% | -$712K |
|
2524
Piper Sandler
PIPR
$5.29B
| $1.25M | ﹤0.01% |
84,684
+5,832
| +7% | +$82.2K |
|
|
XLRN
2525
DELISTED
Acceleron Pharma
XLRN
| $1.25M | ﹤0.01% |
13,140
-32,285
| -71% | -$3.11M |
|
Similar funds
Barclays's Q2 2020 Portfolio in Review
As of Q2 2020, Barclays held 6,627 positions worth $129B, up 2.3% from $127B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Barclays withdrew a net $22.7B in Q2 2020, closing 960 positions and reducing 2,655 holdings. Its most notable exit was Allergan plc, an estimated $735M position sold in full.
By sector, the portfolio is most concentrated in Technology at 9.7% of assets, up from 8.3% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares MSCI ACWI ex US ETF worth $123M.
- Barclays's largest Q2 2020 buy was iShares MSCI ACWI ex US ETF: 2,853,067 shares worth $123M.
- Barclays added most to iShares iBoxx $ High Yield Corporate Bond ETF in Q2 2020, an estimated $984M increase.
- Barclays's biggest Q2 2020 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.98B.
- Barclays fully exited Allergan plc in Q2 2020, selling an estimated $735M.
- Barclays's ten largest holdings make up 34% of its $129B portfolio in Q2 2020.
- Barclays opened 468 new positions and closed 960 in Q2 2020.
- Barclays's portfolio value rose 2.3% quarter-over-quarter to $129B.
Based on Barclays's 13F filing for Q2 2020, filed 12 Aug 2020.